Qlaris Bio to Present New Clinical and Preclinical Data on QLS-111 at 2025 World Glaucoma Congress

Qlaris Bio announced that new data from studies of its lead investigational compound QLS-111 will be presented at the 2025 World Glaucoma Congress (WGC). This will include an oral presentation on clinical data from the recently completed QC-111-201 “Osprey” and QC-111-203 “Apteryx” Phase 2 studies in patients with primary open-angle glaucoma  and ocular hypertension, as well as two poster presentations featuring additional data on QLS-111. The 2025 WGC is being held June 25–28, 2025, in Honolulu, Hawaii.

QLS-111 is a preservative-free, ATP-sensitive potassium channel opener designed to lower IOP by selectively reducing episcleral venous pressure and distal outflow resistance, pathways not completely addressed by currently approved glaucoma therapies. QLS-111 relaxes vasculature tissues distal to the trabecular meshwork, including collector channels, intrascleral vessels, and episcleral vessels. The presentations will underscore QLS-111’s unique mechanism of action and its additive IOP‐lowering benefit when combined with latanoprost monotherapy.

“QLS-111 could be a valuable adjunct to currently available IOP lowering drugs and drainage devices given its complementary mechanism, regardless of baseline IOP,” said Barbara Wirostko, MD, FARVO, chief medical officer of Qlaris Bio. “We are especially impressed by theopportunity for QLS-111 to provide strong additive IOP-lowering efficacy in addition to prostaglandins, compared to current adjunctive therapies. As a preservative-free topical eye drop with an excellent safety profile free of added hyperemia at the 0.015% dose, it can offer an improvement in long-term compliance and adherence.”

The schedule of scientific presentations is as follows:
Saturday, June 28, 4:30 – 5:30 pm HST
QLS-111 significantly lowers IOP in Phase 2 studies, Osprey and Apteryx, as monotherapy and adjunctive therapy with excellent safety and tolerability
Presenter: Barbara Wirostko, MD, FARVO, Qlaris Bio
Session: Medical Treatment and Non-Incisional Surgery | Abstract ID: WGCABS-1579

Friday, June 27, 4:45 – 5:45 pm HST
Preclinical assessment of QLS-111, a novel ATP-sensitive potassium channel opener, alone and in combination with approved ocular hypotensive drugs
Lead Author: Prof. Michael Fautsch, PhD, Mayo Clinic
Poster #: WGCABS-1373

Friday, June 27, 4:45 – 5:45 pm HST
Safety, tolerability, and ocular hypotensive efficacy of QLS-111, a novel ATP-sensitive potassium channel opener added to latanoprost monotherapy – QC-111-203 ‘Apteryx’ Clinical Study
Lead Author: Dr. Barbara Wirostko
Poster #: P-PW-0395